Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature

2018 ◽  
Vol 38 (12) ◽  
pp. 2337-2343 ◽  
Author(s):  
Döndü Üsküdar Cansu ◽  
Erdal Bodakçi ◽  
Cengiz Korkmaz
Keyword(s):  
Case Report ◽  
Side Effect ◽  
Review Of The Literature ◽  
Rare Side Effect ◽  
Dose Dependent

Bevacizumab-induced dysphonia: A case report with brief review of literature

2019 ◽  
Vol 26 (4) ◽  
pp. 1032-1036
Author(s):  
So Yi Lam ◽  
Chung-Shien Lee ◽  
Sandhya Sharma ◽  
Kit Cheng
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Side Effect ◽  
Case Reports ◽  
Palliative Therapy ◽  
Ovarian Adenocarcinoma ◽  
Voice Changes ◽  
Patient Reported ◽  
Rare Side Effect

Introduction Anti-angiogenic treatment in adjunct with chemotherapy is widely used for the treatment of various cancers. These agents inhibit vascular endothelial growth factor (VEGF) signaling thereby inhibiting tumor proliferation and invasion. Dysphonia, or voice changes, has been documented, but is an underreported side effect of anti-angiogenic agents. We report a case of intermittent dysphonia in a patient with metastatic, platinum-refractory ovarian cancer treated with bevacizumab. Case report A 48-year-old female with high grade mixed type ovarian adenocarcinoma and concurrent left sided breast cancer was transitioned to palliative therapy with gemcitabine-bevacizumab for her ovarian cancer. At a follow-up visit after three cycles of the new therapy, the patient complained of intermittent changes in her voice, describing periods of hoarseness or softness in her voice after the chemotherapy—sometimes to the point that her voice was inaudible. Management and outcome: A new pelvic thrombus was discovered upon assessment of the patient’s disease. Bevacizumab was held and she was referred to ear, nose, and throat evaluation for dysphonia. Laryngoscopic examination showed normal vocal cord, with normal movements and no lesion or necrosis. During subsequent follow-up, the patient reported improvement in her voice with no additional dysphonia. Discussion Vocal adverse effects of anti-VEGF agents have been documented in landmark trials and case reports; however, clinicians are often unaware of this rare side effect. Although VEGF-induced dysphonia may be rare and may not impede the patient’s quality of life in some cases, it is critical to acknowledge and not underestimate this adverse effect.

scholarly journals Pleural Effusion: A Rare Side Effect of Nilotinib—A Case Report

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Hava Üsküdar Teke ◽  
Olga Meltem Akay ◽  
Deniz Gören Şahin ◽  
Mustafa Karagülle ◽  
Eren Gündüz ◽  
...  
Keyword(s):  
Case Report ◽  
Pleural Effusion ◽  
Tyrosine Kinases ◽  
Side Effect ◽  
Chronic Phase ◽  
Rare Side Effect

Pleural effusion, as a side effect of tyrosine kinases, may be seen as most commonly associated with dasatinib and very rarely seen with nilotinib. In this report we present a chronic phase of CML case that was treated with nilotinib due to imatinib (Gleevec) allergy and had pleural effusion with nilotinib at 5th year of treatment. If pleural effusion develops in patients taking nilotinib and if this effusion is exudative and lymphocyte predominant, after ruling out pulmonary and cardiac etiologies, it must be associated with nilotinib; according to stage of effusion drug should be discontinued and/or steroid should be started and/or surgery should be performed.

scholarly journals Hypereosinophilia as a Rare Side Effect of Methotrexate in a Patient with Erythrodermic Psoriasis: The First Case Report

2019 ◽  
Vol 10 (4) ◽  
Author(s):  
Thanh Thai Van Le ◽  
Chuyen Thi Hong Nguyen ◽  
Hao Trong Nguyen ◽  
Chau Van Tro ◽  
Giang Huong Tran ◽  
...  
Keyword(s):  
Case Report ◽  
Side Effect ◽  
First Case ◽  
Rare Side Effect ◽  
Erythrodermic Psoriasis

scholarly journals Statin-Induced Neuropathic Pain: A Case Report

2020 ◽  
Author(s):  
Nima Vaziri ◽  
Habib Mofakham ◽  
Fanak Fahimi
Keyword(s):  
Adverse Effect ◽  
Neuropathic Pain ◽  
Case Report ◽  
Peripheral Neuropathy ◽  
Statin Therapy ◽  
Side Effect ◽  
Severe Form ◽  
Rare Side Effect

The most reported form of statin induced pain is myalgia, conversely peripheral neuropathy is a rare side effect. We report a patient who received rosuvastatin for hypercholesterolemia and experienced episodes of pain in both hands during the night. Rosuvastatin was stopped and atorvastatin was replaced. Re-introduction with another statin resulted in a more severe form of the similar adverse effect after 4 months. This is a rare adverse effect of a extensively prescribed class of drug. Physicians should be aware of the possibility of peripheral neuropathy symptoms in patients on statin therapy. J Pharm Care 2019; 7(4): 120-122.

scholarly journals RIFAXIMIN INDUCED HYPONATREMIA: A CASE REPORT

2016 ◽  
Vol 9 (9) ◽  
pp. 1 ◽  
Author(s):  
Shalini Upadhyay ◽  
Prabhat Agrawal ◽  
Manish Bansal ◽  
Anjalika Gupta
Keyword(s):  
Irritable Bowel Syndrome ◽  
Case Report ◽  
Clinical Practice ◽  
Side Effects ◽  
Side Effect ◽  
Aged Woman ◽  
Rare Side Effect ◽  
Middle Aged Woman ◽  
The Common ◽  
Irritable Bowel

ABSTRACTRifaximin is one of the common drugs used in clinical practice in the management of traveler’s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug. We hereby present the case of a middle-aged woman who was a known caseof IBS: Diarrhea predominant who developed symptoms of hyponatremia after a short duration of rifaximin treatment, no other cause of hyponatremiawas found on evaluation, so we suspect this as a rare side effect of rifaximin therapy.Keywords: Rifaximin, Hyponatremia, Irritable bowel syndrome.

Sign in / Sign up

Export Citation Format

Share Document